Feb 18, 2026Partial Epigenetic Reprogramming for Vision Loss: Life Biosciences ER-100 TrialLife Biosciences received FDA clearance to begin the first human trial of partial epigenetic reprogramming using OSK Yamanaka factors delivered via AAV for glaucoma and NAION. Trial is in early stages; no human efficacy data exists yet.
Feb 13, 2026Alpha-Ketoglutarate and Aging: TET Enzyme Activity, Epigenetic Clocks, and Ca-AKG TrialsAlpha-ketoglutarate (AKG) is a TCA cycle intermediate that activates TET enzymes involved in DNA demethylation. The TRIIM-X trial using Ca-AKG reported a reduction in biological age markers. Evidence is preliminary but mechanistically credible.
Feb 9, 2026Calcium Alpha-Ketoglutarate and Epigenetic Aging: Biological Age Reduction EvidenceCalcium alpha-ketoglutarate (Ca-AKG) is an intermediate in the Krebs cycle and an alpha-ketoglutarate-dependent dioxygenase co-factor critical for epigenetic regulation. A clinical trial showed an 8-year reduction in biological age by DNA methylation clock. Evidence is early but striking.